Therefore, these epigenetic markers can effectively detect colorectal tumors developing along either the adenomatous or the serrated pathway of tumorigenesis, and they tend to be found across most lesions unlike mutations (e.g., those involving KRAS or BRAF, which are identified in only ~ 40% and ~ 10% of colorectal neoplasms, respectively). Here, BRAF is linked to colorectal neoplasm.